On June 5, June 5, the state administration of food and drug administration issued the announcement of the second batch of overrepeated drug messages (no. 70 2017).
296 drugs were overrepeated.
The general administration reminded the relevant pharmaceutical companies and research and development agencies to make prudent investment in business decisions. Provinces, autonomous regions and municipalities directly under the food and drug supervision and administration department should strengthen the related site verification to accept an application for drug registration, development and production site inspection, to have the release of excessive repeated drug varieties, take the initiative to do propaganda work, rational development and guide enterprises to declare.
Announcement, administration, said entrusted Chinese medicine institute, this directory is already approved the sales situation of listed drugs from 2013 to 2015, monitoring analysis according to conform to have formed an approval number 20 or more, and the sample hospitals (CMEI) monitoring in 3 years sales companies of 20 or more conditions, an approval number or meet has won approval number formed 20 or more, and sample pharmacy (RDM) monitoring for 3 years in the number of the approval document for the pin companies of 20 or more conditions of generic varieties selection, a total of 294 varieties selected, involving the classification of clinical pharmacology and therapeutics of 13 categories, 59, now make a public announcement. A list of 13 new varieties has been released from the original catalogue, compared with the list released in 2016.
Attached: excessive duplicate catalogue